B.I.T. BREAST IN TRANSLATION 3.0

• MARIA VITTORIA DIECI· DIRIGENTE MEDICO
• CLAUDIO VERNIERI· DIRETTORE

• ANA MAFALDA ANTUNES DE MELO E OLIVEIRA· RELATORE
• UMBERTO CILLO· RELATORE
• CARMINE DE ANGELIS· MODERATORE
• MANON DE GRAAF· RELATORE
• MASSIMO DI MAIO· MODERATORE
• MARIA VITTORIA DIECI· RELATORE
• GIAN PAOLO FADINI· RELATORE
• THEODOROS FOUKAKIS· MODERATORE
• GAIA GRIGUOLO· TUTOR
• VALENTINA GUARNERI· RELATORE
• FRANCESCA LIGORIO· TUTOR
• LUCA MAGNANI· RELATORE
• LUCA MALORNI· MODERATORE
• CATERINA MARCHIÒ· RELATORE
• DAVIDE MASSA· RELATORE
• FEDERICA MIGLIETTA· TUTOR
• BRENNO PASTÒ· RELATORE
• STEFANO PICCOLO· MODERATORE
• LEONARDO PROVENZANO· RELATORE
• ROBERTO RUGA· RELATORE
• CLAUDIO VERNIERI· RELATORE

Ragione sociale

DELPHI INTERNATIONAL SRL

Stato accreditamento

STANDARD - 1° rinnovo

Di processo

Bit 2026 aims to provide a brain-shaking, translational forum where clinicians and scientists explore the latest insights into metastatic dissemination, site-specific vulnerabilities, tumor heterogeneity, and the pre-metastatic niche. The program has the goal of inspiring the next generation of clinical scientists to think beyond algorithms and guidelines. In addition to scientific sessions, bit 2026 will also foster critical reflection on the culture of oncology and research, addressing themes such as ambition, visibility, role models and work–life balance. By blending science with discussions on the professional and human dimensions of our field, bit 2026 seeks to build a community committed to excellence, integrity, and innovation in metastatic breast cancer research and care.

#3Documentazione clinica. Percorsi clinico-assistenziali diagnostici e riabilitativi, profili di assistenza - profili di cura

Area: Obiettivi formativi tecnico-professionali

Partecipanti max

100

Verifica presenza

Sistema Elettronico A Badges

Verifica apprendimento

Questionario A Risposta Multipla Online